|Target||Spike protein of SARS-CoV-2|
|Other names||LY-CoV1404, LY3853113|
Possible side effects include itching, rash, infusion-related reactions, nausea and vomiting.
Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death. Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.
Bebtelovimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in February 2022. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in people aged 12 years of age and older weighing at least 40 kilograms (88 lb) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.
Bebtelovimab is not authorized for people who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with bebtelovimab has not been studied in people hospitalized due to COVID-19.
Bebtelovimab emerged from a collaboration between Eli Lilly and AbCellera. Bebtelovimab was discovered by AbCellera and the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.
Society and culture
- "FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant" (Press release). U.S. Food and Drug Administration (FDA). 11 February 2022. Retrieved 12 February 2022. This article incorporates text from this source, which is in the public domain.
- "Emergency Use Authorization (EUA) Of Bebtelovimab" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 12 February 2022.
- "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bebtelovimab" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 12 February 2022.
- "Frequently Asked Questions on the Emergency Use Authorization of Bebtelovimab for the Treatment of COVID-19" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 12 February 2022.
- "Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19" (Press release). Eli Lilly and Company. 11 February 2022. Retrieved 12 February 2022 – via PR Newswire.
- "AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19" (Press release). AbCellera. 11 February 2022. Retrieved 12 February 2022.
- "Bebtelovimab (Code C182122)". National Cancer Institute. Retrieved 12 February 2022. This article incorporates text from this source, which is in the public domain.
- World Health Organization (2021). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 126 – COVID-19 (special edition)". WHO Drug Information. 35 (4): 1130–1.
- "Bebtelovimab". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT04634409 for "A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)" at ClinicalTrials.gov